Regenerative medicines global revenues down by 40% but ‘poised for growth’

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/Natali_Mis)
(Image: Getty/Natali_Mis)

Related tags: Regenerative medicine, cell and gene therapy, Cell therapy, Cell and gene therapy catapult

The global market for regenerative medicines raised $4.8bn in the first half of 2019; a slowdown compared to the same period of 2018, though the sector is poised for additional growth, says ARM CEO.

A report​ published by the Alliance for Regenerative Medicine (ARM), reports that global revenues for the regenerative medicines reached $2.6bn (€2.32bn) in the first half of the year, a 38% decrease compared to the same period of 2018.

That figure includes companies in the booming cell and gene therapies market as well as companies focusing on tissue engineering.

Despite the decrease, due to ‘global market forces,’ industry experts are not worried, as the sector is poised for growth, according to Janet Lambert, CEO of ARM.

“As evident in the data, 2018 represented a watershed financial year for this sector, as numerous companies had significant IPOs and several blockbuster follow-on financings,” ​Lambert told Biopharma-Reporter, adding that the investment climate was robust, as numerous products came to market.

“However, in Q4 2018, we saw global market forces affect these financings,”​ and this has continued in 2019, Lambert added, commenting on the figures presented in the Q2 2019 report.

Regenerative medicines market revenues

ARM’s CEO suggests that despite this slowdown in the public markets, financings from corporate partnership upfront payments as well as venture capital sources have been strong, “with mid-year 2019 data measuring already 50% or more of what we saw in full-year 2018.”

“The sector is poised for additional growth, as a rich pipeline is producing positive data and numerous products expected to come to market in the very near-term,” ​Lambert told us.

Specifically, the pipeline is expected to significantly expand as the ongoing clinical trials for cell and gene therapies and tissue engineering worldwide were 1,069 at the close of the second quarter of 2019.

Regenerative medicines clinical trials

Out of those, 60% of the products in development are oncology treatments and 6% are being investigated for the treatment of central nervous system (CNS) disorders, according to ARM.

The report also showed that in Europe and Israel, 234 therapeutic developers have raised $1.3bn in the first half of 2019, demonstrating a 17% increase from 2018. There are currently 266 clinical trials underway sponsored by companies headquartered in Europe.

Regarding the development for treatments of rare disease, there were 562 ongoing gene therapy clinical trials, and $3.1bn has been raised to develop these therapies in the first half of 2019.

Regenerative medicines development companies

Related news

Show more

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us

Products

View more

Webinars